Latest News
- Freight Surge and Gulf Tensions Threaten India’s Pharma Exports; Industry Flags Potential ?5,000-Crore Impact
- India Scales Up HPV Vaccination, Screening in Cervical Cancer Elimination Push: Health Minister J.P. Nadda
- Teva Secures $400 Million from Blackstone Life Sciences to Advance Late-Stage IBD Therapy Duvakitug
Novosibirsk Pharmaceutical Manufacturing Company Renewal to increase drug production by 1.5 times
The expansion is planned to be based on the establishment of new infrastructure, which will include a manufacturing workshop and a logistics centre.
Novosibirsk Pharmaceutical Manufacturing Company (PFK) Renewal, which produces 220 drug names and holds up to 3% of the Russian market, plans to increase production 1.5 times, according to TASS, Russian News Agency.
The expansion is planned to be based on the establishment of new infrastructure, which will include a manufacturing workshop and a logistics centre. Investments will remain at 2022 levels, amounting to up to 3 billion rubles per year, according to Renewal CEO Vladlen Kalustov. He also stated that the company's sales in 2022 amounted to more than 145 million packages.
Renewal has already begun production of 40 new drugs in 2021, 50 in 2022, and 60 in 2023. "We intend to produce generics of imported drugs. And the company's entire strategy in the coming years is aimed at replacing imported drugs," said Vladimir Grechkin, the company's executive director, in 2022.